World Heart Day — September 29
Fighting with our whole heart.
CVD affects all races, ethnicities, genders and age groups. The good news is, premature heart attacks and strokes are largely preventable.1 On World Heart Day — and every other day of the year — make sure your patients know the risks and how to avoid them.
Testing is the best weapon we have in the fight against CVD
Your patients’ chances of contracting cardiovascular diseases can be greatly reduced by establishing good habits. Encourage them to be active, keep their weight and blood pressure under control, avoid tobacco, eat a heart-healthy diet, and take the time to learn about cholesterol, blood sugar and diabetes.2
Of course, family history and age play a role as well. For example, postmenopausal women have a higher risk for heart disease as their bodies' production of estrogen drops.3 The best way of assessing risk is routinely testing your patients for high blood pressure, high cholesterol, and diabetes1 — and to control their numbers over time.
Rapid diagnostic solutions to help you fight CVD
It’s believed that the two most common predictors for CVD are atherosclerosis and hypertension. Counseling and medicines can treat both risk factors — reducing the probability of the condition recurring or worsening, and prevent future complications.
Elevated cholesterol is one of the major risk factors for coronary heart disease, heart attack and stroke. As the blood cholesterol rises, so does the cardiovascular disease risk. Many patients, such as those with metabolic syndrome, have comorbid conditions such as high lipids and diabetes. And if other risk factors are present such as smoking, high blood pressure or diabetes, the risk increases even further.
But the first step is an accurate diagnosis.
Early detection is essential to cardiac care. At Abbott, we offer comprehensive cardiac solutions that are a natural fit for a wide range of outpatient settings – including physician offices, clinics, community health centers, hospital and long-term care facilities, emergency rooms, and hospital outpatient clinics. Our assays and analyzers provide accurate, reliable results with rapid turnaround time, aiding clinicians in providing better patient care.
Guidelines around the world support measuring a Lipid Panel/Cholesterol every five years in healthy adults, more regularly if you have other risk factors, in children and youths who are at an increased risk and to evaluate the success of lipid-lowering treatment.12, 13, 14
Both the Cholestech LDX™ System and the The Afinion™ Lipid Panel offer point-of-care testing for cholesterol and related lipids to serve as diagnostic tools that provide information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes.
Patient’s whose cardiac conditions become critical resulting in an acute myocardial infarction (MI) need rapid responsive care to improve patient outcomes. Rapid with-patient diagnostic testing, especially troponin, may increase the overall quality of care and drive timely treatment for patients experiencing ACS. Troponin is the preferred biomarker for aiding in the diagnosis of acute myocardial infarction (MI), according to guidelines from the American College of Cardiology (ACC). Troponin tests can provide early detection of the elevation cycle and predict myocardial injury with cell death in order to prevent further damage.7,8
Incorporating point-of-care serial troponin testing into standardized order sets and protocols for suspected ACS patients could lead to improved diagnostic accuracy for patients presenting with suspected acute MI. 9,10 In addition, administering point-of-care troponin testing may improve the time to result for these critical patients, and potentially decrease costs associated with traditional laboratory-based diagnostic testing.11
Accurate, actionable results from the leader in point-of-care lipid testing.
The CLIA-waived Cholestech LDX System helps monitor your at-risk patients. Engineered for confidence, this analyzer provides accurate, actionable, and readily accessible results for point-of-care lipid profile, cholesterol, and glucose testing.
Simply more efficient.
Lipid profiles are essential clues to assessing your patients’ risk of heart disease. The Afinion™ Lipid Panel test and the fully automated Afinion™ 2 Analyzer will give you the test results you need in the moment — so you’re able to make highly informed treatment decisions while your patient is still in your office.
Test for the quantitative determination of Total Cholesterol (Chol), High-Density Lipoprotein cholesterol (HDL), Low-Density Lipoprotein cholesterol (LDL), Triglycerides (Trig), non-HDL and Chol/ HDL ratio in whole blood, serum and plasma, used in the diagnosis and treatment of lipid disorders.